Darren Cline Biography and Net Worth

Mr. Cline has more than 30 years of experience in the biopharma industry as an accomplished commercial executive. He has collaborated with R&D across in all stages of development across numerous therapeutic areas including oncology. Mr. Cline has held various leadership roles of increasing scale and complexity at industry-leading companies including Amgen, InterMune, Alexion, Seagen and most recently, GW Pharmaceuticals, where he served as Chief Commercial Officer. Mr. Cline served on the Board of Stemline Therapeutics prior to the acquisition by Menarini Group.

What is Darren S. Cline's net worth?: The estimated net worth of Darren S. Cline is at least $351,252.09 as of June 12th, 2018. Mr. Cline owns 72,723 shares of Pyxis Oncology stock worth more than $351,252 as of April 18th. This net worth estimate does not reflect any other assets that Mr. Cline may own. Learn More about Darren S. Cline's net worth.
How do I contact Darren S. Cline?: The corporate mailing address for Mr. Cline and other Pyxis Oncology executives is , , . Pyxis Oncology can also be reached via phone at 617-221-9059 and via email at [email protected]. Learn More on Darren S. Cline's contact information.
Has Darren S. Cline been buying or selling shares of Pyxis Oncology?: Darren S. Cline has not been actively trading shares of Pyxis Oncology over the course of the past ninety days. Most recently, on Wednesday, December 8th, Darren S. Cline bought 10,000 shares of Pyxis Oncology stock. The stock was acquired at an average cost of $9.39 per share, with a total value of $93,900.00. Learn More on Darren S. Cline's trading history.
Who are Pyxis Oncology's active insiders?: Pyxis Oncology's insider roster includes Thomas Civik (Director), and Darren Cline (Director). Learn More on Pyxis Oncology's active insiders.
Are insiders buying or selling shares of Pyxis Oncology?: During the last twelve months, Pyxis Oncology insiders bought shares 6 times. They purchased a total of 33,426 shares worth more than $58,503.10. During the last twelve months, insiders at the sold shares 3 times. They sold a total of 31,541 shares worth more than $70,146.10. The most recent insider tranaction occured on September, 27th when CAO Jitendra Wadhane bought 2,500 shares worth more than $4,675.00. Insiders at Pyxis Oncology own 8.4% of the company. Learn More about insider trades at Pyxis Oncology.
Information on this page was last updated on 9/27/2023.

Darren S. Cline Insider Trading History at Pyxis Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/8/2021	Buy	10,000	$9.39	$93,900.00

Darren S. Cline Buying and Selling Activity at Pyxis Oncology

Pyxis Oncology Company Overview

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $4.83

$4.74

$5.09

50 Day Range

MA: $5.16

$3.65

$6.59

2 Week Range

Now: $4.83

$1.35

$6.85

Volume

573,288 shs

Average Volume

816,341 shs

Market Capitalization

$280.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Urgent alert: open this for a huge profit potential

From Timothy Sykes | Ad

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here